No of outpatients at Tokyo cancer hospital drops by almost half amid virus pandemic msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Feb 22, 2021
This study was conducted to analyse the changes in Treatment Behavior during the COVID-19 Pandemic among Patients at a Cancer Hospital. The number of new outpatients and patients receiving surgery at a cancer hospital in Japan drastically decreased under and even after the state of emergency. SARS-CoV-2 infection can result in severe COVID-19 and high mortality among cancer patients. This indicates that patients without established care patterns lost opportunities for cancer diagnosis and treatment. Emergency measures were first implemented in Tokyo and six other prefectures. As it was previously reported, the incidence of COVID-19 among cancer patients was low, even for symptomatic patients with typical computed tomography findings. The patient behavioral changes related to treatment during the pandemic in cancer hospitals have not been thoroughly investigated.
relapsed or refractory chronic lymphocytic leukaemia progression after 12 months vs. 68% for comparators AstraZeneca s Calquence (acalabrutinib), a next-generation, selective Bruton s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]). The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the ASCEND Phase III trial and a Phase I trial in Japanese patients, showing Calquence monotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus a standard treatment of rituximab, a monoclonal antibody, combined with the physician s choice of idelalisib, a PI3-kinase inhibitor or bendamustine, a chemotherapy.